Our Clinical Focus

Bone & Joint Care in China

Joint preservation, microsurgical replantation, and patient-specific 3D-printed reconstruction — built around your next decision, often at a fraction of US cost.

If you have been told you need a knee replacement, hip replacement, spine fusion, or complex bone reconstruction, it may be worth taking a closer look first.

China's orthopedic centers combine China-developed surgical robotics (TiRobot, used in over 110,000 procedures across 200+ hospitals), innovative biomaterials (the COLTRIX cartilage scaffold and Bone-02 fracture adhesive — both China-NMPA-approved firsts), and high-volume experience across the full treatment spectrum — from joint preservation to 3D-printed custom reconstruction. The hardest question is often not whether treatment exists; it is whether the treatment recommended to you is truly the right next step.

MediPath coordinates pre-arrival expert review and hospital matching to help you decide.

X-ray of the human pelvis and hip joints
01 / 03New Drugs

Globally-leading Chinese biologics for inflammatory and autoimmune joint disease.

China's musculoskeletal drug pipeline is anchored by telitacicept — the world's first BAFF/APRIL dual-target biologic, approved 2021 — alongside the first selective Chinese JAK1 inhibitor ivarmacitinib and two new biologics in NMPA review (QX002N/crusekitug and TRD221). For international patients with inflammatory or autoimmune joint disease, this is access to globally-leading Chinese-originated biologics not yet available outside China.

World's 1st

dual BAFF/APRIL-targeting biologic (telitacicept, 2021) — no other approved biologic targets both pathways in a single molecule[R3-R4]

70.4–75.1%

ACR20 response with ivarmacitinib (4 mg / 8 mg) at Week 24 versus 40.4% with placebo in Phase III rheumatoid arthritis[R1-R2]

2 in review

additional China-originated joint/autoimmune biologics advancing through NMPA review — QX002N (IL-17A) and TRD221 (osteoarthritis)[R5][R6]

02 / 03New Treatments

Doing less when less is enough — and more, more precisely, when complexity demands it.

China's musculoskeletal surgical pathway begins with what doesn't need replacement, fusion, or major reconstruction — joint preservation, microsurgical replantation, patient-specific 3D-printed reconstruction. The world's first published hand replantation was performed in Shanghai in 1963 by Chen Zhongwei; today his pathway anchors China's microsurgery and limb-salvage care.

1963

year of the world's first published successful limb replantation — Shanghai Sixth People's Hospital (Prof. Chen Zhongwei)[R18-R19]

96

patient cohort of 3D-printed custom hemipelvic reconstruction at West China Hospital, with sustained functional gains and reduced pain[R9]

7–10 mm

incision for endoscopic lumbar spine decompression (PELD/PTED/UBE) — an alternative to open or fusion surgery, at high Chinese case volume[R8]

03 / 03New Technology

Chinese biomaterials and devices, proven at clinical scale.

China-developed platforms span the full bone & joint care journey: TiRobot (NMPA-approved domestic orthopedic surgical robot, deployed at 200+ Chinese hospitals), the COLTRIX collagen scaffold for cartilage repair (NMPA Innovative Medical Device 2023), the Bone-02 injectable bone adhesive (frontier biomaterial), domestic 3D-printed titanium endoprosthesis systems, and lower-limb rehabilitation robotics. The story is Chinese biomaterials and devices increasingly proven at clinical scale.

2023

NMPA approval of the China-developed COLTRIX collagen scaffold for cartilage repair — an innovative-device first[R10]

~3 min

bone-fragment fixation time reported with the Bone-02 injectable adhesive via a 2–3 cm incision (Sir Run Run Shaw Hospital)[R15]

2 platforms

China-developed orthopedic surgical robots approved by NMPA for hip/knee arthroplasty — TiRobot (Tinavi) and SkyWalker (MicroPort)[R13-R14]

Request a Bone & Joint Case Review

Share your diagnosis, imaging (X-ray, CT, MRI), prior treatment history, and the surgery that has been recommended to you. Our team can help identify whether China offers a relevant second opinion — joint preservation before replacement, microsurgical or limb-salvage reconstruction, endoscopic spine surgery, or access to China-originated biologics — or faster, lower-cost access to a pathway for your condition.